DVT treatment at home: Low-molecular-weight heparin is safe, effective

July 1996
Geriatrics;Jul96, Vol. 51 Issue 7, p61
Academic Journal
Focuses on two studies suggesting that patients with acute proximal thrombosis often can be treated safely at home with subcutaneously administered low-molecular-weight heparin. Comparison with standard-in-hospital intravenous heparin.


Related Articles

  • Breaking out of the silo:One health system's experience. Vichiendilokkul, Anna // American Journal of Health-System Pharmacy;10/15/2002, Vol. 59 Issue 20, pS15 

    Pharmacoeconomic evidence for inpatient deep vein thrombosis (DVT) treatment with low-molecular-weight heparins (LMWHs) and one health system's experience with this treatment compared with unfractionated heparins (UFHs) are examined, Applying clinical and pharmacoeconomic evidence to clinical...

  • Tinzaparin. Reddy, Prabashni // Formulary;Sep2000, Vol. 35 Issue 9, p725 

    Discusses the use of the low-molecular-weight heparin (LMWH) tinzaparin for the treatment of deep vein thrombosis (DVT). Drug administration; Chemistry and pharmacology; Pharmacokinetics; Results of clinical trials. INSET: Formulary Considerations.

  • Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. Leizorovicz, A.; Simonneau, G.; Decousus, H.; Boissel, J.P. // BMJ: British Medical Journal (International Edition);7/30/94, Vol. 309 Issue 6950, p299 

    Compares the efficacy and safety of low molecular weight heparins and unfractionated heparins in the treatment of deep venous thrombosis in France. Reduction in the incidence of thrombus extension in low molecular weight heparin; Occurrence of major hemorrhages; Total percentage of mortality.

  • Low-molecular-weight heparin may reduce hospital stays.  // Mayo Clinic Health Letter;Dec1996, Vol. 14 Issue 12, p4 

    Reports on the use of low-molecular-weight heparin for deep-vein thrombosis (DVT). Description of DVT; Nonrequirement of intense monitoring of therapy.

  • Oral Low Molecular Weight Heparin Absorption. Leon-Bay, Andrea; O'Shaughnessy, Catherine; Agarwal, Rajesh; Rivera-Schaub, Theresa; Rosado-Gray, Connie; Gerspach, Linda; Baughman, Robert A. // Pharmaceutical Technology North America;Mar2002, Vol. 26 Issue 3, p38 

    Examines the effectiveness of parental low molecular weight heparin (LMWH) for the prevention of deep vein thrombosis in patients with joint replacement or abdominal surgery. Description on the delivery of agent-mediated LMWH; Replacement of warfarin to prevent pulmonary embolism; Delay on the...

  • Enoxaparin lowers risk of DVT after total hip replacement.  // Geriatrics;Nov96, Vol. 51 Issue 11, p64 

    Presents an abstract of the article `Risk of Deep-Venous Thrombosis After Hospital Discharge in Patients Having Undergone Total Hip Replacement: Double-Blind, Randomised Comparison of Enoxaparin Versus Placebo,' by A. Planes, N. Vochelle, et al, published in the 1996 edition of the `Lancet'...

  • Adjusted Subcutaneous Heparin or Continuous Intravenous Heparin in Patients with Acute Deep Vein Thrombosis. Doyle, D. J.; Turpie, A. G. G.; Hirsh, J.; Best, C.; Kinch, D.; Levine, M. N.; Gent, M. // Annals of Internal Medicine;Oct87, Vol. 107 Issue 4, p441 

    Presents a study which determined the efficacy and safety of adjusted subcutaneous calcium heparin compared with continuous intravenous calcium heparin in the treatment of acute deep vein thrombosis. Effectiveness of treatment; Clinical manifestations of recurrent venous thrombosis; Objectives...

  • Preface [Hot topic: Antithrombotic Agents Executive Editor : Ho-Sam Ahn ]. Ho-Sam Ahn, Frank // Current Pharmaceutical Design;Nov2003, Vol. 9 Issue 28, p1 

    Coronary heart disease leading to heart attack and ischemic stroke are the two most prevalent causes of mortality and morbidity in the United States. Thrombosis is the most important pathological mechanism underlying heart attack and stroke. The key role of platelets in arterial thrombosis was...

  • Benefit-risk assessment of treatments for heparin-induced thrombocytopenia. Messmore, Harry L.; Jeske, Walter P.; Wehrmacher, William H.; Walenga, Jeanine M.; Messmore, Harry; Jeske, Walter; Wehrmacher, William; Walenga, Jeanine // Drug Safety;Jul2003, Vol. 26 Issue 9, p625 

    Patients with heparin-induced thrombocytopenia (HIT) are at high risk of thrombosis and should be treated with alternative anticoagulant therapy to reduce complications. The current treatment of choice is one of the approved direct thrombin inhibitors, argatroban or lepirudin. These drugs have...


Other Topics